Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | MERTK | Q12866 | 2/20 | 0.49 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18616304 | 0.85 | MAP4K3 (0.60) | METNTRK1MAP4K3JAK2 | |
| SCHEMBL30388408 | 0.82 | MET (0.55) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL21776509 | 0.82 | MET (0.55) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL29914439 | 0.82 | MET (0.55) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL23617090 | 0.82 | MET (0.55) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL2680817 | 0.82 | MET (0.49) | METFGFR1FGFR2FGFR3MAP4K3 | |
| SCHEMBL2386565 | 0.81 | AXL (0.59) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL18615853 | 0.81 | AXL (0.57) | METNTRK1FGFR1FGFR2FGFR3 | |
| SCHEMBL992793 | 0.80 | MAP4K3 (0.43) | METAXLMERTKMAP4K3JAK2 | |
| SCHEMBL992070 | 0.80 | ERN1 (0.55) | METFGFR1FGFR2FGFR3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | MET 3052/4885NTRK1 2179/4885FGFR1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.